University of Maryland Engineers Open Door to Big New Library of Tiny Nanoparticles


news story image

The development of bimetallic nanoparticles (i.e., tiny particles composed of two different metals that exhibit several new and improved properties) represents a novel area of research with a wide range of potential applications.

Now, a research team in the University of Maryland (UMD)’s Department of Materials Science and Engineering (MSE) has developed a new method for mixing metals generally known to be immiscible, or unmixable, at the nanoscale to create a new range of bimetallic materials.

Such a library will be useful for studying the role of these bimetallic particles in various reaction scenarios such as the transformation of carbon dioxide to fuel and chemicals.

The study, led by MSE Professor Liangbing Hu, was published in Science Advances on April 24, 2020. Chunpeng Yang, an MSE Research Associate, served as first author on the study.

“With this method, we can quickly develop different bimetallics using various elements, but with the same structure and morphology,” said Hu. “Then we can use them to screen catalytic materials for a reaction; such materials will not be limited by synthesizing difficulties.”

The complex nature of nanostructured bimetallic particles makes mixing such particles difficult, for a variety of reasons—including the chemical makeup of the metals, particle size, and how metals arrange themselves at the nanoscale—using conventional methods.

This new non-equilibrium synthesismethod exposes copper-based mixes to a thermal shock of approximately 1300 ̊ Celsius for .02 seconds and then rapidly cools them to room temperature. The goal of using such a short interval of thermal heat is to quickly trap, or ‘freeze,’ the high-temperature metal atoms at room temperature while maintaining their mixing state.

In doing so, the research team was able to prepare a collection of homogeneous copper-based alloys. Typically, copper only mixes with a few other metals, such as zinc and palladium—but by using this new method, the team broadened the miscible range to include copper with nickel, iron, and silver, as well.

“Using a scanning electron microscope (SEM) and transmission electron microscope (TEM), we were able to confirm the morphology – how the materials formed – and size of the resulting Cu-Ag [copper-silver] bimetallic nanoparticles,” Yang said.

This method will enable scientists to create more diverse nanoparticle systems, structures, and materials having applications in catalysis, biological applications, optical applications, and magnetic materials.

As a model system for rapid catalyst development, the team investigated copper-based alloys as catalysts for carbon monoxide reduction reactions, in collaboration with Feng Jiao, a professor in the Department of Chemical and Biomolecular Engineering at the University of Delaware.

The electro-catalysis of carbon monoxide reduction (COR) is an attractive platform, allowing scientists to use greenhouse gas and renewable electrical energy to produce fuels and chemicals.

“Copper is, thus far, the most promising monometallic electrocatalyst that drives carbon monoxide reduction to value-added chemicals,” said Jiao. “The ability to rapidly synthesize a wide variety of copper-based bimetallic nanoalloys with a uniform structure enables us to conduct fundamental studies on the structure-property relationship in COR and other catalyst systems.”

This non-equilibrium synthetic strategy can be extended to other bimetallic or metal oxide systems, too. Utilizing artificial intelligence-based machine learning, the method will make rapid catalyst screening and rational design possible.

For additional information:

Yang, C., et al. (24 April 2020). Overcoming Immiscibility Toward Bimetallic Catalyst Library, Science Advances. DOI: 10.1126/sciadv.aaz6844

Re-Thinking The Future – Clean Disruption and the Collapse of the Oil, Coal and ICEV Industries


Man-in-VR-Headset-Looking-into-Portal-Future-of-VR

Pandemics, Negative Oil Prices, Political Divisiveness, Economic Warfare, Shifting Population Profiles ….

“It was the best of Times … It was the Worst of times.” (Charles Dickens – A Tale of Two Cities) Perhaps a little of Dickens could be said to be true of our current times.

But to quote another Author, Coach and Inspirational Leader,

“Great Moments are born from Great Opportunity.” – Herb Brooks – 1980 Gold Medal Hockey Coach, ‘Miracle on Ice’

And that … THAT is exactly what we have here, right now.

These very well may be the Times, the Technological Disruptions and the Opportunity … that changes the Social, Economic and Structural Fabric of Our World.

Tony Seba a world-renowned author, thought leader, speaker, educator ( Stanford University) and entrepreneur is sharing his future vision with us in his new YouTube Video:

“Re-Thinking the Future – Clean Disruption and the Collapse of the Oi, Coal and ICEV Industries”

 

Editor of “Great Things from Small Things”I believe it is Our Moment and Our Time as Entrepreneurs, Innovators and Leaders to Create, Shape and Build Our Future.

“The Wind and the Waves are Always on the side of the ablest Navigators.” – E. Gibbons

 

 

 

Promising Lithium Production from US Sedimentary Deposits – America’s ‘Lithium Valley’ may be Key to New Energy Economy


Lithium is an essential component of electric vehicle batteries which occurs abundantly in the Earth’s crust in many different forms, roughly classified as pegmatites (“hard rock”), brines, and sedimentary deposits (which you may sometimes hear erroneously generalized as “clays”)

America’s Lithium Valley

Do you think driving a Tesla or plugging-in to solar power are environmentally-conscious choices? Then you should know it’s almost certain the batteries in those systems traveled around the world two or three times before they were even installed. That’s not very “green,” is it? Lithium-ion batteries, found in so many things we use every day, often have a rather costly carbon footprint. That could soon change with a discovery that’s just a couple hours north of Tesla’s Gigafactory. A Canadian mining company, LithiumAmericas, identified what’s one of the world’s largest lithium deposits inside the footprint of an ancient volcano. NBCLX Storyteller Chase Cain takes us to the ancient volcano in Nevada that could hold the future of a green energy boom in the West.

Currently, only pegmatite and brine resources are used to produce lithium chemical products commercially.

But a host of new players aiming to produce lithium using sedimentary deposits in Western North America and around the world are coming on the scene.

The sedimentary deposit projects claim to take advantage of favorable chemistry of processing the sediments, sometimes described as the “best of both worlds” when compared to pegmatites and brines. In this article, I will share what are some of the most promising features of sedimentary deposit projects, who’s working on developing these deposits, and why investors and mainstream capital markets should take them seriously as future sources of lithium chemical products. It will be helpful to understand some of the pros and cons of processing pegmatites and brines into lithium chemical products to understand the “best of both worlds” argument for the sedimentary deposits.

Pegmatites

In pegmatites, lithium is strongly bound in crystal structures like aluminosilicates (Al, Si oxides) and because the lithium is so tightly bound in the structure, the mineral requires aggressive processing to remove it to make lithium chemicals.

Spodumene [(LiAl(SiO3)2] is the most widely mined lithium-bearing pegmatite, and has been successfully developed into a significant source of lithium commercially (representing around half of global supply in 2019). It is first dug up and crushed to smaller pieces. The crushed material is then “upgraded” to remove waste materials from the mine that are not spodumene and don’t contain lithium. Once upgraded, calcination (heating to ~1,000°C) is used to convert the crystal to a different structure that is more amenable to removing the lithium.

These high temperatures are typically generated using coal or natural gas, meaning the carbon footprint of roasting pegmatites is typically higher than processing of other lithium resources.

The roasting is a fundamental aspect of extraction of lithium from spodumene because of their crystal structure, and it is difficult to get around this. Some other pegmatites may not require this roasting step however.

img_1752 Lithium Mining in Nevada

This calcination process is followed by a chemical treatment to extract the lithium. This gives a mostly pure lithium concentrate (called the leachate) which can be refined into lithium chemical products with a relatively simple technological approach involving addition of chemicals.

Pegmatites are a good source of lithium because they are easy to manipulate from a mining engineering perspective, and the leachate obtained from the chemical treatment isn’t heavily contaminated with elements with similar chemical characteristics to lithium (ex. alkali/alkaline earths like Na, K, Mg, Ca, Sr), meaning the impurities are easy to remove from the leachate. The waste produced from spodumene operations can be simply put aside or used for other applications like concrete manufacturing and other applications.

Lithium can be produced from other minerals like lepidolite and zinnwaldite using similar flowsheets to spodumene, but some modifications are required depending on the unique mineralogy.

Brines

Brine resources are very different from pegmatites from a lithium extraction and processing perspective.

Brines are high concentration salty reservoirs in which salts are dissolved (ex. Li, Na, K, Mg, Ca, Sr are common cations, or positively charged species, while Cl, SO4, BO3, and CO3 are common anions, or negatively charged species, in these resources). The minerals in brines start off as volcanic materials but over millions of years, rain and geochemical phenomena cause them to dissolve in water and concentrate in basins. Brines can be as high as 20-40% salt by mass, meaning that if you were to evaporate away the water from the brine, around 20-40% of the mass would be left behind as white or clear crystals.

img_1753

Read More: US Lithium Mining May Get a Boost …

Brines are liquid, meaning that they need to be pumped to the surface for processing, not dug up and crushed like pegmatites are mined. This means that they do not require roasting or leaching operations to put the lithium into solution for further processing – the lithium is already dissolved. There are two ways to remove lithium from brines.

First, evaporation pond systems can be used to evaporate the water from the brine, leaving behind contaminant salts and an “end brine” of mostly lithium chloride which is processed into lithium carbonate by adding sodium carbonate. This process only works for high lithium concentration brines with low impurities in places with no rainfall, and there is concern that if brine is pumped out from too deep in the salar, freshwater may be sucked in, diluting the salar and destroying potable water resources used by humans.

Second, direct lithium extraction (DLE) processes can be used to remove lithium from the natural brine to produce a highly pure concentrate, leaving behind a “spent brine” containing all the original components of the natural brine but without the lithium. This spent brine needs to be reinjected and/or separated from the natural brine so that the two don’t mix, or else the natural lithium-bearing brine will be diluted by the spent brine containing no lithium, making it impossible to extract more lithium from the reservoir.

image-asset.png?format=750w

Sedimentary Deposits

As mentioned above, sedimentary deposits are considered to share some of the positive attributes of both pegmatites and brines. Sedimentary deposits are created when lithium is washed out of volcanic materials into basins where the salts and minerals dry, creating chemical structures in which the lithium is bound up in a mineral, but much less strongly compared to pegmatite resources. They typically have the consistency of dirt, not hard rock, and often break up when placed in water. If the lithium was not bound in a mineral at all, it would wash out in water forming a brine (this is typically not observed).

A number of leading projects are proposing not using any roasting, meaning the lithium is bound in the mineral with an “intermediate” strength compared to pegmatites and brines. A chemical leach is used to extract the lithium from the sediment, after which the waste sediment can be stored in mounds or back-filled into an open pit.

The lack of requirement to roast the sediment is a positive asset for these resources because it means that natural gas pipelines may not necessarily need to be built to process the sediment. Some projects report requiring upgrading of the sediment ore to remove contaminants which would “unnecessarily” consume acid, and in October 2019, only one project is proposing to use a roasting step in their flowsheet. The benefit of processing a sediment containing “loosely bound” lithium is that the solid waste can be easily disposed of without diluting the original resource, similar to the waste materials from after removing lithium from pegmatites.

The sedimentary deposit projects have some promising attributes for a future of supplying lithium to the battery industry, but reagent inputs will need to be optimized thoroughly for each individual project. Every sediment is different and the flowsheets of the different projects may look quite different. The chemistry of the sediments varies significantly (which is also the case for brines), and each project will need to take this into account. Currently, most public pre-feasibility studies show that tens to hundreds of times excess of reagents are used to create the lithium leachates. This implies low lithium concentrations in the leachate compared to pegmatite-derived leachates, and high concentrations of impurities like Na, K, and Mg.

This explains why most projects currently propose by-product sales to reduce apparent OPEX (electricity, sulfuric acid, boric acid, potash, etc.) because these are likely high OPEX flowsheets if they were “pure play” lithium.

Further, the high porosity and low particle size of the sediments mean that they “hold on” to leachate during leaching, and solid/liquid separations will be key to extracting most of the lithium as leachate from the spent ore. When this is done poorly, the ore “gums up” and a significant amount of lithium is lost with the waste.

The “in between” strength of how lithium is chemically bound in sediments results in some of their “best of both world” characteristics when compared to brines and pegmatites, and these strengths should be taken advantage of in future flowsheet development. New leaching techniques and reagent management flowsheets may be helpful in unlocking these sedimentary materials to produce high lithium concentration, low impurity concentration leachates that can be more easily processed into battery quality lithium chemical products. The sedimentary deposit lithium projects are young, but I believe that some of them will be built in the near future.

The healthy mining jurisdiction of Western North America, proximity of the deposits to American battery manufacturers, and potential for low carbon intensity means that they have excellent potential for helping supply lithium for batteries in the near future, and that they should be followed closely.

A map of these projects is seen below.

image-asset.png?format=750w

Acknowledgments

Thanks to all those who influenced this article through including Anna WallTom BensonGene Morgan, and Davd-Deak

University of Waterloo developing DNA-based COVID-19 vaccine


Researchers at the University of Waterloo are developing a DNA-based vaccine that can be delivered through a nasal spray.

Researchers at the University of Waterloo are developing a DNA-based vaccine that can be delivered through a nasal spray.

The vaccine will work by using bacteriophage, a process that will allow the vaccine to replicate within bacteria already in the body and is being designed to target tissues in the nasal cavity and lower respiratory tract.

“When complete, our DNA-based vaccine will be administered non-invasively as a nasal spray that delivers nanomedicine engineered to immunize and decrease COVID-19 infections,” explains Roderick Slavcev, a professor in the School of Pharmacy who specializes in designing vaccines, pharmaceuticals and gene-therapy treatments. “This research combines the expertise of many and leverages existing technology developed by my team, which we’re reconfiguring for a COVID-19 application.”

When completed, the researchers aim to have the DNA-based vaccine enter cells in targeted tissues and cause them to produce a virus-like particle (VLP) that will stimulate an immune response in people.

The VLP will look similar to the structure of SARS-CoV-2 (the virus which causes COVID-19), but is harmless. This similarity will activate the body’s natural immune response to protect against viral infections comparable to the VLP, including SARS-CoV-2. It will also bind to receptors that SARS-CoV-2 would bind to, limiting the possible sites for transmission. By causing these changes in the body, the vaccine will build immunity against COVID-19 and decrease the severity of infections in progress – serving as both a therapeutic and a vaccine.

Every detail of the vaccine, from ensuring the bacteriophage target specific cells in the respiratory tract to creating a minimal VLP to impersonate SARS-CoV-2, is specifically engineered by the researchers and requires testing.

To achieve the design of such a complex project, Slavcev is teaming up with Emmanuel Ho, another professor at the School of Pharmacy, and Marc Aucoin, professor of chemical engineering. Ho’s team is designing the nanomedication that will be delivered by the nasal spray, which is currently being tested. Aucoin’s lab is constructing and purifying the VLP and boosting immunity following the initial administration of the therapeutic vaccine.

“It is the collaborative effort of our talented teams that makes this multidisciplinary project so feasible and necessarily efficient as a potential universal vaccine solution against SARS-CoV infections,” says Slavcev. “To practice science with such urgency alongside such talented colleagues and their students is not only immensely educational, it is extremely rewarding.”

Slavcev’s team has completed design of the bacteriophage delivery system and is currently modifying this system to apply to COVID-19.  Additional design of components and further testing will take place later this year. Components of the research are supported by a grant from the Natural Sciences and Engineering Research Council of Canada.

Note: This research has not yet been peer-reviewed and is being released as part of UWaterloo’s commitment to help inform Canada’s COVID-19 response.

Covid-19 Diagnostic Based on MIT Technology to be Tested on Patients Soon


MIT-Covid-Research-Roundup-01_0

This scanning electron microscope image shows SARS-CoV-2 (yellow)—also known as 2019-nCoV, the virus that causes COVID-19—isolated from a patient, emerging from the surface of cells (blue/pink) cultured in the lab. Image: NIAID-RML

A variety of MIT research projects could aid efforts to detect and prevent the spread of coronavirus.

As more Covid-19 cases appear in the United States and around the world, the need for fast, easy-to-use diagnostic tests is becoming ever more pressing. A startup company spun out from MIT is now working on a paper-based test that can deliver results in under half an hour, based on technology developed at MIT’s Institute for Medical Engineering and Science (IMES).

Cambridge-based E25Bio, which developed the test, is now preparing to submit it to the FDA for “emergency use authorization,” which would grant temporary approval for using the device on patient samples during public health emergencies.

Elsewhere around MIT, several other research groups are working on projects that may help further scientists’ understanding of how coronaviruses are transmitted and how infection may be prevented. Their work touches on fields ranging from diagnostics and vaccine development to more traditional disease prevention measures such as social distancing and handwashing.

Faster diagnosis

The technology behind the new E25Bio diagnostic was developed by Lee Gehrke, the Hermann L.F. von Helmholtz Professor at IMES, and other members of his lab, including Irene Bosch, a former IMES research scientist who is now the CTO of E25Bio.

For the past several years, Gehrke, Bosch, and others in the lab have been working on diagnostic devices that work similar to a pregnancy test but can identify viral proteins from patient samples. The researchers have used this technology, known as lateral flow technology, to create tests for Ebola, dengue fever, and Zika virus, among other infectious diseases.

The tests consist of strips of paper that are coated with antibodies that bind to a specific viral protein. A second antibody is attached to specialized nanoparticles, and the patient’s sample is added to a solution of those particles. The test strip is then dipped in this solution. If the viral protein is present, it attaches to the antibodies on the paper strip as well as the nanoparticle-bound antibodies, and a colored spot appears on the strip within 20 minutes.

Currently, there are two primary types of Covid-19 diagnostics available. One such test screens patient blood samples for antibodies against the virus. However, antibodies are often not detectable until a few days after symptoms begin. Another type of test looks for viral DNA in a sputum sample. These tests can detect the virus earlier in the infection, but they require polymerase chain reaction (PCR), a technology that amplifies the amount of DNA to detectable levels and takes several hours to perform.

“Our hope is that, similar to other tests that we’ve developed, this will be usable on the day that symptoms develop,” Gehrke says. “We don’t have to wait for antibodies to the virus to come up.”

If the U.S. Food and Drug Administration grants the emergency authorization, E25Bio could start testing the diagnostic with patient samples, which they haven’t been able to do yet. “If those are successful, then the next step would be to talk about using it for actual clinical diagnosis,” Gehrke says.

Another advantage of this approach is that the paper tests can be easily and inexpensively manufactured in large quantities, he adds.

RNA vaccines

On Feb. 24, only about a month after the first U.S. case of coronavirus was reported, the Cambridge-based biotech company Moderna announced it had an experimental vaccine ready to test. That speedy turnaround is due to the unique advantages of RNA vaccines, says Daniel Anderson, an MIT professor of chemical engineering, who also works on such vaccines, though not specifically for coronavirus.

“A key advantage of messenger RNA is the speed with which you can identify a new sequence and use it to come up with a new vaccine,” Anderson says.

Traditional vaccines consist of an inactivated form of a viral protein that induces an immune response. However, these vaccines usually take a long time to manufacture, and for some diseases, they are too risky. Vaccines that consist of messenger RNA are an appealing alternative because they induce host cells to produce many copies of the proteins they encode, provoking a stronger immune response than proteins delivered on their own.

RNA vaccines can also be quickly reprogrammed to target different viral proteins, as long as the sequence encoding the protein is known. The main obstacle to developing such vaccines so far has been finding effective and safe ways to deliver them. Anderson’s lab has been working on such strategies for several years, and in a recent study he showed that packing such vaccines into a special type of lipid nanoparticles can enhance the immune response that they produce.

“Messenger RNA can encode the viral antigens, but in order to work, we need to find a way to deliver these antigens to the correct part of the body so that they get expressed and generate an immune response. We also need to make sure that the vaccine causes appropriate immune stimulation to get a strong response,” Anderson says.

Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), has estimated that it will take at least 12 to 18 months to fully test any potential Covid-19 vaccine for safety and effectiveness.

Keep your distance

Over the last decade, Lydia Bourouiba, an associate professor directing the Fluid Dynamics of Disease Transmission Laboratory at MIT, has focused on characterizing and modeling infectious disease dynamics and transmission at various scales. Through experiments in the lab and clinical environment, she has reported that when a person coughs or sneezes, they do not emit a spray of individual droplets that quickly fall to the ground and evaporate, as scientists had once thought. Instead, they produce a complex cloud of hot and moist air that traps droplets of all sizes together, propelling them much further through the air than any individual droplet would travel on its own.

On average, her experiments have revealed that a cough can transmit droplets up to 13 to 16 feet, while a sneeze can eject them up to 26 feet away. Surrounding air conditions can act to further disperse the residual droplets in upper levels of rooms.

Bourouiba notes that the presence of the high-speed gas cloud is independent of the type of organism or pathogen that the cloud may contain. The droplets within it depend on pathogenesis coupled with a patient’s physiology — a combination which her laboratory has focused on deciphering in the context of influenza. She is now expanding her studies and modeling to translate the work to Covid-19, and says now is a critical time to invest in research.

“This virus is going to stay with us for a while — and certainly data suggest that it is not going to suddenly disappear when the weather changes,” she says. “There’s a fine and important balance between safety, precautions and action that is important to strike to enable and dramatically accelerate research to be done now so we can be better prepared and informed for actions in the weeks and months to come when the worst of the pandemic will unfold.”

She is also working with others to evaluate ways to limit a cloud’s dispersal and slow Covid-19 transmission to health care workers and others in shared spaces. “A surgical mask is not protective against inhalation of a pathogen from the cloud,” she says. “For an infected patient wearing it, it can contain some of the forward ejecta from coughs or sneezes, but these are very violent ejections and masks are completely open on all sides, and fluid flows through the path of least resistance.”

Based on the data, she recommends that health care workers consider wearing a respirator, whenever possible. And, for the general public, Bourouiba emphasizes that the risk of contracting COVID-19 remains relatively low locally, and that risk should be thought of in the context of the community.

Wash those hands

Another good way to protect yourself against all of those tiny infectious droplets is to wash your hands. (Again, and again, and again.)

Ruben Juanes, an MIT professor of civil and environmental engineering, and of earth, atmospheric and planetary sciences, published a study in December showing the importance of improving rates of handwashing at key airports in order to curtail the spread of an epidemic. Now, he says, following the Covid-19 outbreak, governments around the world have imposed unprecedented restrictions on mobility, including the closure of airports and suspension of flight routes.

At the same time, the World Health Organization, U.S. Centers for Disease Control, and many other health agencies all recommend hand-hygiene as the number one precaution measure against disease spread. “Following our recent paper on the impact of hand-hygiene on global disease spreading,” Juanes says, “we are now investigating the combined effect of restrictions on human mobility and enhanced engagement with hand-hygiene on the global spread of COVID-19 through the world air-transportation network.”

Juanes says he and Christos Nicolaides PhD ’14, a professor at the University of Cyprus who was the lead author of the previous study, are working “with fine-grained, worldwide air-traffic data that accounts for all flights for the period between Jan. 15, 2020 until today (accounting for closures/cancellations) and the corresponding period of 2019 (base level) to elucidate the role of travel restrictions on the global spread of Covid-19 through detailed epidemiological modeling.”

“Furthermore,” he adds, “we simulate different hand-hygiene strategies at airports on top of travel restrictions with the goal of proposing an optimal strategy that combines travel restrictions and enhanced hand hygiene, to mitigate the advance of Covid-19 both in the short term (weeks) and the long term (the next flu season).”

Juanes says they will make the results immediately available via medarXiv, while the work follows peer-review in a journal. This would also allow the information to reach other academic and government institutions in a more timely way, he says.

The New Rules for Remote Work: Pandemic Edition from Harvard Business School


Welcome to the new world of remote work, where employees struggle to learn the rules, managers are unsure how to help them, and organizations get a glimpse into the future. 

With more people working remotely right now, many of us have experienced a videoconference interrupted by barking dogs or hungry kids demanding snacks, punctuated, perhaps, by cabinet doors slamming and ice makers grinding in the background. We all understand, of course—we’re living it, too. 

Welcome to the new world of remote work, pandemic style. 

Before the coronavirus hit, 5.2 percent of US employees reported telecommuting most of the time, while 43 percent worked from home at least some of the time. Now, with the pandemic shuttering workplaces, that figure has skyrocketed globally. 

But remote work during this bizarre time, with so many people scrambling to get their work done while sharing close quarters with shut-in kids, spouses, and pets, is certainly not business as usual, even for work-from home veterans. While some of the typical remote work rules apply, others don’t. Business leaders need a new game plan.

We asked Harvard Business School professors to provide practical advice for managing large-scale, long-term remote work at a time when many employees are not only distracted by the commotion in their homes, but are shaken by the crisis unfolding outside their doors. 

“MANAGERS SHOULD MAKE THE CALL ON HIGH-LEVEL PRIORITIES, SO EMPLOYEES CAN FOCUS ON THEIR BEST WORK.”

Here are 10 ways that leaders can support employees who are working remotely during an unprecedented and uncertain time:  

1. Communicate clearly and be decisive

Business leaders have already had to make difficult decisions, such as closing offices or eliminating travel, but now they should express in black-and-white terms how employees’ work priorities should change as a result of these business disruptions. 

If certain non-essential tasks are too difficult to pull off from home, take them off the table or at least put them on a back burner for now, and let workers know which projects should be prioritized, says HBS Senior Lecturer Julia Austin, who provides leadership coaching to companies. 

“While now is a time to foster trust and delegate, you don’t want people debating about whether they should or shouldn’t do a major project. All that time questioning what to do will impact productivity,” Austin says. “Managers should make the call on high-level priorities, so employees can focus on their best work.” 

At a time when many business leaders can’t gather their staffs in the same room, they need to “show up” on videoconference or in email to update workers regularly about how their companies are pivoting to weather this crisis and are protecting employees worried about their jobs, says HBS professor Tsedal Neeley, the Naylor Fitzhugh Professor of Business Administration, who has researched how to fix broken global teams. 

“They may not be able to completely reassure workers about what will happen tomorrow, but they can provide a glimpse of the big picture from their perspective,” says Neeley, who is writing a case about a leader of a US company whose entire China operation was shut down and has seen no revenue, with thousands of employees home, since November. 

2. Lead by example

Managers should model the behavior they want to see in others. If they say employees can leave the office or avoid travel, but the manager keeps popping into the workplace and hitting the road, workers may feel guilty staying home. 

“Leaders underestimate how much what they do is mirrored by their employees,” Austin says. “Hypocrisy degrades them.

Employees not only want to be told what to do, they want their managers to follow through on everything they’re saying, so they don’t feel pressure to keep up or start questioning their own performance.” 

3. Be extra flexible

The beauty of classic remote work is the breathing room for employees to take a walk, throw in a load of laundry, or start dinner, all while getting more work done by avoiding unnecessary office meetings and traffic-snarled commutes. 

But right now, with offices, schools, and day cares closed, those time-on-your-side benefits have evaporated for many remote workers who no longer have the house to themselves and are struggling with the tremendous challenge of focusing on work while balancing the demands of family members. 

So, this period requires a new frontier of flexibility, the professors say. Managers should ask employees what challenges they face and allow workers the freedom to choose their own best windows of time to get work done, whether at the crack of dawn, late at night, or in two-hour shifts with breaks throughout the day. 

“Managers should yield to the expertise and knowledge of their subordinates and let them decide the best times and ways for them to work right now,” Neeley says. 

If the team is working on a project that is time-critical, one option is to ask employees about their availability so everyone knows not to expect an immediate response during certain chunks of the day. And, if a manager starts sending out emails on Sunday mornings because that’s her own best time to work, she should make it clear that her subordinates need not reply until Monday. 

“EMPLOYERS SHOULD UNDERSTAND THE FUNDAMENTAL SHIFT IN EMPLOYEES’ LIVES AND RECOGNIZE THAT THEY HAVE TO RADICALLY ALTER THEIR WORK EXPECTATIONS.”

4. Adjust work expectations 

With business practices changing as the result of widespread remote work, some workers have too much to do and others have too little, and some may have a tougher time getting work done than others. Whenever possible, managers should trust workers to make decisions about what they can and cannot accomplish, Neeley says.

And based on input from employees, managers may want to evaluate each employee’s workload and ability to handle the work under the current circumstances and shift projects around as needed, Austin says. 


More tips for remote workers

Unsure of your footing when it comes to working at home? Remote work expert Prithwiraj Choudhury answers all your questions. 

Readers Ask: I Need Tips for Working at Home


In some cases, it might even be appropriate for employers to decrease workloads for now and reevaluate when working hours should return to normal, says Lakshmi Ramarajan, the Anna Spangler Nelson and Thomas C. Nelson Associate Professor of Business Administration. 

Her research suggests that employer expectations can create conflicts between employees’ personal and professional identities, decreasing their performance and commitment. 

“Employers should understand the fundamental shift in employees’ lives and recognize that they have to radically alter their work expectations until this crisis winds down,” Ramarajan says. “An employee with young kids at home, or someone taking care of elder relatives, or a worker needing to focus on their own physical and mental health as a result of the situation will not be able to do a 40-hour workweek.” 

Wikimedia, the nonprofit organization behind Wikipedia, is telling staff and contractors they can work 20 hours per week and still get paid for 40. “Work is not the only thing on people’s minds right now. Their families, their bills, childcare and school closures, the economy … we are all trying to manage a lot,” CEO Katherine Maher wrote. “It is unreasonable and unrealistic to expect someone to be fully present, eight hours a day, when they have a three-year-old with crayons drawing on the wall, or an elderly parent who needs help navigating the stairs.” 



On the flip side, some employees are working more than usual now—partly to prove they’re still plugging away when they can’t be seen. “There’s this pressure to say to your supervisor, ‘Yes, I’m here!’ by making yourself super available at all hours,” Austin says. 

Managers should discourage workers from being “heroes,” Austin says. “If an employee is cranking at home because he’s good at it, but his colleagues are struggling, don’t start assigning all the work to him,” she says. “Managers should be patient and give people time to catch up, so you’re not adding pressure to anyone’s plate.” 

5. Rethink meetings

Managers should understand that some employees can’t do back-to-back phone or online meetings all day long. “People are still spending too much time in meetings, even though our work and lives have changed significantly,” Austin says. 

If your office has a meeting-heavy culture normally, consider scaling back the total number and length of meetings, Austin says. Could you reduce a get-together that typically lasted an hour in the office to a 30-minute huddle on Zoom if the meeting leader sticks to a clear agenda? 

One of the simplest ways to trim meetings is to move to email, Slack, and other writing-based tools for information-sharing and idea-gathering, and call meetings only for decision-making, says Austin, who has written about how to master team meetings. “Meetings should be reserved for getting things done,” she says. 

At the same time, Neeley notes that for some organizations, additionalcontact with staff and more meeting-based communication may be necessary now, particularly in the early days of adjusting to the remote work world. Research shows that informal conversation benefits remote employees, so she advises managers to devote time during meeting calls to connecting with staff on a personal level, for instance, by asking how everyone is holding up. 

“IT CAN BE HARDER TO PAY ATTENTION TO A LONG MEETING ONLINE VERSUS FACE-TO-FACE.”

Afterward, managers should articulate key outcomes of the meeting using other media like email. “It can be harder to pay attention to a long meeting online versus face-to-face, so some form of redundant communication would be helpful so things don’t slip through the cracks,” Neeley says. 

6. Move to more asynchronous work

Given the disruption to the 9-to-5 workday, employers should decrease “synchronous” work that employees perform simultaneously and increase “asynchronous work” that workers can do on their own time in a Google doc, Slack, or email, says Prithwiraj Choudhury, whose research shows companies often benefit when employees work remotely. Choudhury is the Lumry Family Associate Professor in the Technology and Operations Management Unit. 

“The crisis accentuates what remote companies already understand—that work does not need to happen at the same time,” says Choudhury. “People can wake up in different time zones and cities, open documents, and get going.” 

Those who are new to remote work also need to change their mindset about how quickly to expect responses and learn to practice patience, he says. 

“If you post a message in Slack, trust that people will be responsible and come to it when they can,” he says. “It doesn’t hurt to throw your question in the deep, dark water and wait a few hours. We will all learn that things don’t have to happen right this instant. This is the new norming that needs to happen.” 

7. Accept that productivity will probably suffer

Choudhury’s research shows productivity often increases with remote work. But now, with workers who have never operated this way scrambling to get up to speed while dealing with the anxiety of the virus and distractions at home, this period is not the best litmus test for measuring the productivity of remote work, Choudhury says. 

In fact, companies may need to face the hard truth that productivity could suffer by at least 10 to 20 percent in the short term, Austin says. “I have a client who hung a sheet in his basement because it was the only way he could hide from his kids. And his kids were still handing him notes under the sheet during our call,” she says. “With that happening everywhere, productivity is bound to suffer.” 

Ramarajan says business leaders should send this message: We get it—this isn’t easy. Take care of yourself and your families first. And since employees are concerned about the global health and economic conditions affecting their job security, employers should also reassure them they won’t be penalized if productivity drops, whenever possible. This will generate greater long-term commitment to organizations, she says. 

“Great leaders will share their own struggles about adjusting to their partners being on conference calls in the next room,” Austin says. “People often think that everyone else has it figured out except them. They’ll be relieved to know this isn’t easy for anyone.” 

8. Focus on outcomes rather than monitoring activities

Supervisors who lack experience managing remote workers might seek to keep close tabs on employees—asking them to keep their webcams on all day or alert managers when they take quick breaks. Or they might send emails at 4:45 p.m. to test whether workers are still online. Neeley says this type of micromanaging, which was found, for example, in a Wall Street Journal editor’s leaked memo, sends a hidden message to workers: We don’t trust you.

“THE CRISIS ACCENTUATES WHAT REMOTE COMPANIES ALREADY UNDERSTAND—THAT WORK DOES NOT NEED TO HAPPEN AT THE SAME TIME.”

“It’s terribly intrusive and tone deaf,” says Neeley. “Managers who don’t see the people they’re managing are struggling. They feel like they’re losing control, and their insecurities are creeping in.” She urges managers to let go of commanding by fear and trust they’ve hired competent people who aren’t slacking off. 

One caveat: While most workers thrive with a hands-off approach, Choudhury’s research suggests that junior workers who are new to a company may need additional supervision and guidance while working remotely. 

But in general, rather than monitoring every move employees make, companies should establish work goals and measure individual productivity based on output, he says.

“If you’re on a team in a traditional company, one imperfect measure of productivity is showing up to work every day,” Choudhury says. “Now companies don’t see their workers, so the immediate priority should be to make productivity more objective and measurable to the person, so you don’t worry people are free-riding.” 

9. Take time to empathize

It’s a terrible, uncertain time, and managers need to acknowledge the obvious. After all, employees are worried not just about keeping their jobs and how their business is faring, but about the welfare of their families and friends, their personal finances, and even the logistics of squeezing in a germ-harrowing run to the grocery store. 

Managers might want to give employees space to talk with each other, offer support, and listen. 

“Now, more than ever, teams need empathy and to feel like you are all suffering together,” Austin says. “Everyone is dealing with a crisis that is very real. Managers should show their vulnerabilities by saying, ‘We’re all feeling this.’ After 9/11, crying with my coworkers was one of the most transformational moments in my career. Work teams may bond over this current crisis.” 

10. Let workers blow off steam

With many employees feeling anxious and isolated, companies could set up attendance-optional social events online—coffee breaks, lunch gatherings, happy hours, cooking and crafting classes, talent shows, and even meet-the-pet sessions. 

Knowing that workers are bound to feel some screen fatigue these days, business leaders should encourage self-care by allowing employees to take breaks, naps, and walks between work calls.

“A manager can say, ‘It’s 3 p.m., and it’s been a tough week. Take the rest of the afternoon off and spend time with your loved ones.’ You’d be meeting people where they are by recognizing that everyone is stressed out,” Neeley says. 

While this period of remote work isn’t normal, Choudhury says, the silver lining is that many business leaders who have long been resistant to the idea of remote work may open their eyes for the first time to its benefits, including happier workers, less need for office space, and, for some, a possible bump in productivity over the long haul, once the virus settles down. 

“Now that you’ve opened the door to adopting a remote work culture, it may be hard to go back,” Austin says. “My prediction is that there will be a higher demand for more remote-friendly software solutions, a lot of empty space in office parks, and more workers looking for remote roles.” 

About the Author

Dina Gerdeman is a senior writer at Harvard Business School Working Knowledge.

Tiny Nanoparticles Offer Large Potential for Brain Cancer Treatment


tiny brain nanoparticles 1-tinynanopartFor patients with malignant brain tumors, the prognosis remains dismal. With the most aggressive treatments available, patients are usually only expected to live about 14 months after a diagnosis

This is because, chemotherapy, the most common form of treatment for cancer, is uniquely challenging for   patients. The delicate organ in our skulls is protected by a network of vessels and tissue called the blood-brain barrier that keeps most foreign substances out. Furthermore,  can cause significant damage to the rest of the body if they are not able to target the tumor in a pharmacologically significant dose.

These challenges have plagued scientists for years, but a team of researchers for Yale School of Medicine and Beijing Normal University just published a breakthrough study detailing a new method that offers a promise at treatment. The solution? Nanoparticles.

Nanoparticles, particles that are smaller than wavelengths of visible light and can only be seen under a special microscope, have the potential to pass through the blood-brain barrier. They can also carry drugs to targeted areas of the body, reducing the side effects on the rest of the body. But previous nanoparticles were very complex and not very efficient in penetrating in the brain.

This most recent paper, published in Nature Biomedical Engineering on March 30, 2020, describes a small carbon nanoparticle engineered by the two labs that could both deliver chemotherapy drugs across the blood-brain barrier and mark tumor cells with fluorescence in mice. What’s more, this nanoparticle is incredibly simple—made up of only one single compound.

“The major problems we’ve solved is to improve the delivery efficiency and specificity of nanoparticles,” says Jiangbing Zhou, Ph.D., associate Professor of Neurosurgery and of Biomedical Engineering at Yale School of Medicine. “We created nanoparticles like building a missile. There’s usually a GPS on every missile to guide it into a specific location and we’re able to guide particles to penetrate the brain and find tumors.”

The GPS-like targeting occurs because the nanoparticles engineered to be recognized by a molecule called LAT1, which is present in the blood-brain  as well as many tumors, but not in most other normal organs. As a result, chemotherapy drugs can be loaded on the dots and target tumors while barely affecting the rest of the body. The nanoparticles gain entry to the brain because they’ve been engineered to look like amino acids, which are allowed past the  as nutrients.

The nanoparticles have wider implications than  delivery. They can be stimulated to emit a fluorescence, which helps surgeons locate tumor to remove with greater accuracy.

Still, there’s a long road ahead before this research can be applied in a clinical setting, says Dr. Zhou. “It takes a long time before the technology can be translated into clinical applications,” he says. “But this finding suggests a new direction for developing  for drug delivery to the brain by targeting LAT1 molecules.”


Explore further

Improving drug delivery for brain tumor treatment


More information: Shuhua Li et al. Targeted tumour theranostics in mice via carbon quantum dots structurally mimicking large amino acids, Nature Biomedical Engineering (2020). DOI: 10.1038/s41551-020-0540-y

Journal information: Nature Biomedical Engineering

MIT: Researchers Achieve Remote control of Hormone Release Using Magnetic Nanoparticles


Magnetic Nanoparticles 13-researchersa
MIT engineers have developed magnetic nanoparticles (shown in white squares) that can stimulate the adrenal gland to produce stress hormones such as adrenaline and cortisol. Credit: Massachusetts Institute of Technology

Abnormal levels of stress hormones such as adrenaline and cortisol are linked to a variety of mental health disorders, including depression and posttraumatic stress disorder (PTSD). MIT researchers have now devised a way to remotely control the release of these hormones from the adrenal gland, using magnetic nanoparticles.

This approach could help scientists to learn more about how  release influences mental health, and could eventually offer a new way to treat hormone-linked disorders, the researchers say.

“We’re looking how can we study and eventually treat stress disorders by modulating peripheral organ function, rather than doing something highly invasive in the central nervous system,” says Polina Anikeeva, an MIT professor of materials science and engineering and of brain and cognitive sciences.

To achieve control over hormone release, Dekel Rosenfeld, an MIT-Technion postdoc in Anikeeva’s group, has developed specialized  that can be injected into the adrenal gland. When exposed to a weak magnetic field, the particles heat up slightly, activating heat-responsive channels that trigger hormone release. This technique can be used to stimulate an organ deep in the body with minimal invasiveness.

Anikeeva and Alik Widge, an assistant professor of psychiatry at the University of Minnesota and a former research fellow at MIT’s Picower Institute for Learning and Memory, are the senior authors of the study. Rosenfeld is the lead author of the paper, which appears today in Science Advances.

Controlling hormones

Anikeeva’s lab has previously devised several novel magnetic nanomaterials, including particles that can release drugs at precise times in specific locations in the body.

In the new study, the research team wanted to explore the idea of treating disorders of the brain by manipulating organs that are outside the central nervous system but influence it through hormone release. One well-known example is the hypothalamic-pituitary-adrenal (HPA) axis, which regulates stress response in mammals. Hormones secreted by the , including cortisol and adrenaline, play important roles in depression, stress, and anxiety.

“Some disorders that we consider neurological may be treatable from the periphery, if we can learn to modulate those local circuits rather than going back to the global circuits in the ,” says Anikeeva, who is a member of MIT’s Research Laboratory of Electronics and McGovern Institute for Brain Research.

As a target to stimulate hormone release, the researchers decided on  that control the flow of calcium into adrenal cells. Those ion channels can be activated by a variety of stimuli, including heat. When calcium flows through the open channels into adrenal cells, the cells begin pumping out hormones. “If we want to modulate the release of those hormones, we need to be able to essentially modulate the influx of calcium into adrenal cells,” Rosenfeld says.

Unlike previous research in Anikeeva’s group, in this study magnetothermal stimulation was applied to modulate the function of cells without artificially introducing any genes.

To stimulate these heat-sensitive channels, which naturally occur in adrenal cells, the researchers designed nanoparticles made of magnetite, a type of iron oxide that forms tiny magnetic crystals about 1/5000 the thickness of a human hair. In rats, they found these particles could be injected directly into the adrenal glands and remain there for at least six months. When the rats were exposed to a weak magnetic field—about 50 millitesla, 100 times weaker than the fields used for magnetic resonance imaging (MRI)—the particles heated up by about 6 degrees Celsius, enough to trigger the calcium channels to open without damaging any surrounding tissue.

The heat-sensitive  that they targeted, known as TRPV1, is found in many sensory neurons throughout the body, including . TRPV1 channels can be activated by capsaicin, the organic compound that gives chili peppers their heat, as well as by temperature. They are found across mammalian species, and belong to a family of many other channels that are also sensitive to heat.

This stimulation triggered a hormone rush—doubling cortisol production and boosting noradrenaline by about 25 percent. That led to a measurable increase in the animals’ heart rates.

Treating stress and pain

The researchers now plan to use this approach to study how hormone release affects PTSD and other disorders, and they say that eventually it could be adapted for treating such disorders. This method would offer a much less invasive alternative to potential treatments that involve implanting a medical device to electrically stimulate hormone release, which is not feasible in organs such as the adrenal glands that are soft and highly vascularized, the researchers say.

Another area where this strategy could hold promise is in the treatment of pain, because heat-sensitive ion channels are often found in pain receptors.

“Being able to modulate pain receptors with this technique potentially will allow us to study pain, control pain, and have some clinical applications in the future, which hopefully may offer an alternative to medications or implants for chronic pain,” Anikeeva says. With further investigation of the existence of TRPV1 in other organs, the technique can potentially be extended to other peripheral organs such as the digestive system and the pancreas.


Explore further

The myth behind adrenal fatigue


More information: Dekel Rosenfeld et al. Transgene-free remote magnetothermal regulation of adrenal hormones, Science Advances (2020). DOI: 10.1126/sciadv.aaz3734

Journal information: Science Advances

Bioprinting techniques advance from shape to function – Revolutionizing the toolkit for Regenerative Medicine


Biofab id54829_1

Possible approaches toward the convergence of bioprinting and self-organization to guide the maturation of bioprinted constructs toward the generation of functional tissues. Inspired by the composition of adult, native tissues, multiple progenitor or differentiated cells can be loaded into bioinks to build tissues or organoids. In this approach, the architecture imposed by the printing process will be templating the cell-driven development of the tissue and its subsequent maturation. Alternatively, specific stem and progenitor cells that possess the ability to autonomously organize into submillimeter to millimeter organoids that exhibit salient tissue features can be used as intermediate building blocks and as bioink components. In both processes, the stimuli provided by the biomaterials, their architecture, and bioactive factors included in the bioinks play key roles for driving the acquisition of native functions. (Reprinted with permission by Wiley-VCH Verlag) (click on image to enlarge)

 

Biofabrication is a revolutionizing toolkit for regenerative medicine that allows cells and other biomaterials to be precisely combined and patterned into three-dimensional (3D) constructs through automated, cell-friendly fabrication methods.

One of these methods is bioprinting, an additive 3D-printing method where tissue growth and the behavior of cells can be controlled and investigated by embedding them in a delicate 3D framework.3D bioprinting is a highly-advanced manufacturing platform that allows for the printing of tissue, and eventually vital organs, from cells.

This could open a new world of possibilities for the medical field, while directly benefiting patients who need replacement organs.In the early days of bioprinting, around 2013, the lack of printable materials that could serve as cell-laden bioinks, as well as the limitations of printing and assembly methods, presented major constraints for the usefulness of the technique.Things have changed since then.

With rapid advanced in 3D-printing hardware on one hand and bioink materials on the other, biofabrication techniques have gained significant momentum and provide a powerful approach to tackle major hurdles in the generation of engineered living tissues.While 3D bioprinting is still in its early stages, the remarkable leap it has made in recent years points to the eventual reality of lab-grown, functional organs.

Bioprinted structures are being designed and studied for a wide range of biomedical uses. For instance, researchers have demonstrated 3D-bioprinting of living structures with built-in chemical sensors or to create functional liver tissues. Other potential uses are transplantable grafts for tissue restoration; advanced in vitro models to aid the testing of drugs; and potential alternatives to animal experimentation.With regard to building materials in biofabrication processes, two different types of printable inks can generally be distinguished.

One are biomaterial inks used to print cellular structures on which cells are seeded or that can also be used as surgical tools or implants after fabrication. Many different materials, including thermoplasts and metal powders, can be processed that way. The other types are bioinks – printable formulations that contain living cells.

These two different types of inks have different,sometimes opposing printing requirements. The simultaneous need for these opposing requirements led to the conceptualization of the biofabrication window, the range of material properties suitable both for printability with high shape fidelity and for the support of cell function.

In a recent review in Advanced Materials (“From Shape to Function: The Next Step in Bioprinting”), the authors summarize key strategies that have expanded the biofabrication window and that lead to improved control over shape. Building on such advances in material science, their main focus is on the current and future steps toward mimicking salient functionalities of living tissues, through the creation of hierarchically structured constructs, in particular when using bioinks as building blocks for extrusion-based bioprinting.

The review discusses the impact of bioprinted constructs with preformed spatial organization to facilitate tissue morphogenesis. The authors highlight recent and upcoming developments in biofabrication that could influence the next generation of engineered tissues. They point out that the recent progress in hydrogel design together with the development of new bioprinting strategies, have introduced effective solutions to extend the biofabrication window, reducing the need to compromise on the use of materials that display satisfactory structural properties, but provide a nonoptimal environment for cells to thrive.Cell functionality is necessary both for in vitro models and to move forward toward the demonstration of applicability of bioprinted constructs as biomedical devices that can eventually be used as clinical solution to repair damaged tissues, and bring researchers a step closer toward the ambitious goal of functional bioprinting.Despite this remarkable progress, scientists are only beginning to tap into the potential of biofabrication in aiding the reconstruction of fully functional living engineered tissues.

Finally, the authors urge that future strategies embrace biological (developmental) processes and integrate them with bioprinting technologies to yield constructs with biological function toward the ambitious goal of printing functional tissues or even entire organs.

By 

Copyright @Nanowerk

MIT: The coronavirus test that might exempt you from social distancing—if you pass – An Update


MIT COVID 0420 gettyimages-1212775374webA demonstration of a covid-19 blood test developed by Surescreen Diagnostics. C. FURLONG Image

There is a lot of hype around the potential for antibody testing to help get us back outside sooner rather than later. Here’s how it works.

MIT Technology Review: Neel V. Patel

On Monday, President Trump announced that the US had tested over a million patient samples for coronavirus, by far more than any other country in the world. Though the horrendously slow rollout of testing has already set America back in its effort to stop the spread of covid-19, testing is still vital. To beat the virus and stop its spread, says the World Health Organization, we need to identify those who are infected and isolate them, as well as those at risk (who ought to be self-isolating too, whether they are symptomatic or asymptomatic). We also need to figure out which communities can expect to see a rise in coronavirus cases, and where to allocate resources in anticipation of rising hospitalizations.

As reported by MIT Technology Review a few weeks ago, there’s also a serious need for us to find out who has already been infected and is now, presumably, immune to the virus (at least for a while). Since the coronavirus outbreak began, many different groups have ramped up their efforts to develop a serological test that looks for antibodies to the virus—an indication of whether an individual was once infected. Should a test like this ever become available to the public, it could radically shape how we decide who gets to leave home and return to some semblance of normal life.

You can read all our coverage of the coronavirus/Covid-19 outbreak for free, and also sign up for our coronavirus newsletter. But please consider subscribing to support our nonprofit journalism.

Here are the biggest things you should know about the status of antibody testing for covid-19. 

A Berlin Biotech Company Got a Head Start on Coronavirus Tests

Why do we want antibody testing?

Many infected individuals experience only mild or moderate symptoms that clear out fairly quickly. Since there are simply not enough test kits to go around, a lot of people who aren’t showing more severe symptoms are being turned away for testing. Those individuals (myself included) are effectively in limbo, having no way to verify if they were once sick and now potentially immune, or still at risk of being sick and spreading the virus. Moreover, if we’re not able to test everyone, we have no way to really answer questions such as how widespread the infection is, what the true fatality rate is, and what kinds of measures to stop the spread are actually working.

Antibody testing that’s made available en masse might be able to help answer some of those basic questions. Once we have a better understanding of how immunity works with the coronavirus, it could also give survivors of the infection confirmation that they are now immune, meaning they no longer pose a threat to others and could potentially return to work and public life. This would be especially critical for clinics and hospitals experiencing staffing shortages, or infrastructure and utilities providers who need properly trained workers to keep things like our power grids running.

How does it work?

When the body is introduced to a pathogen, the immune system develops tailor-made antibodies that act against the infection. Antibodies can last a long time—anywhere from a couple of years to a lifetime, depending on the disease. During the period that immunity lasts, your body is prepared to ramp up production of those antibodies to neutralize the threat should it ever appear again.

An antibody test, also known as a serology test, analyzes a patient’s serum—the liquid portion of blood that excludes cells and clotting factors but includes antibodies. Many of these tests are simple and require only a small sample, like a finger prick. In this case, through a technique like ELISA (enzyme-linked immunosorbent assay), clinicians look for antibodies that were made in response to the large protein that sticks out of the coronavirus’s surface. A viral fragment is placed on a plate. If there’s an antibody in the patient sample, it will attach to this “spike” protein. Another antibody, engineered by the clinicians and capable of attaching to the first antibody, is introduced to the solution. When they bind, the new antibody will activate an enzyme that changes the color of the solution, indicating that the patient has the antibodies we’re looking for, and has therefore been exposed to the coronavirus.

How is this different from the testing we already do?

The way we’re testing infections right now is by looking for viral genetic material in patient samples. Using a method called polymerase chain reaction (PCR), clinicians can amplify any coronavirus RNA in a patient’s nasal swab so its presence can be confirmed. Viral DNA or RNA can be found in the body as soon as an infection begins, even if you’re asymptomatic. But it disappears soon after the immune system clears the infection out. So this type of test is useful to find out who is currently infected, but not who once was infected.

Antibodies, on the other hand, aren’t developed until several days after infection has taken hold, so they aren’t a useful indicator of who is currently infected. But because they’re around in the blood in large numbers for many months after infection, they would be extremely useful to identify past cases long after the infection has been beaten.

How much does it cost?

A serological test for coronavirus antibodies is much less costly than a PCR test that looks for coronavirus genetic material. California-based Biomerica, for example, sells a serological test for less than $10. A PCR test for covid-19 can cost up to $51 under Medicare. 

How fast is it?

You can get results from a serological test in just minutes. Many groups are working on versions that can be run at home, with no need to send samples to a lab. A PCR test takes hours to run, and because samples must typically be shipped back and forth from the testing site, patients usually don’t get results for at least several days (although the FDA is fast-tracking a portable point-of-care genetic test for coronavirus that’s supposed to take less than 15 minutes).

Who’s working on this?

Many, many groups. Singapore, China, and other countries have already conducted limited numbers of antibody testing. A group led by virologist Florian Krammer at the Icahn School of Medicine at Mount Sinai in New York City recently developed an ELISA-based antibody test for covid-19. American companies like Biomerica and Chembio Diagnostics (from New York) are selling antibody tests outside the US, with aggressive plans to get these kits up to snuff for FDA approval. BioMedomics of North Carolina, in collaboration with medical tech company BD, just launched a point-of-care test that can be administered at the doctor’s office and give results in 15 minutes. The UK has its own test, developed by Public Health England, and recently ordered 3.5 million kits to be distributed by Amazon and pharmacies around the country in just a matter of days.

What are the limitations?

Since we still don’t know how long covid-19 immunity lasts, the presence of antibodies is not a guarantee a person is totally immune to future reinfection. Similarly, antibodies can’t be used to determine whether someone is still contagious—a follow-up PCR test might be necessary to rule out an ongoing infection. In other words, you’d want to test positive for immunity through an antibody test (even well after the infection is cleared), and negative for the virus through a PCR test.

There is a huge concern about the accuracy of serological tests. PCR testing, for all its drawbacks, is still considered pretty accurate. In an antibody test, however, a patient might test positive for covid-19 because of antibodies against a different coronavirus (like ones that cause the common cold). Two patients might be infected and recover at about the same time, but one’s antibody test might not stay positive as long as the other’s. And again, there is a huge window of uncertainty because it could take up to a week for a body to start generating antibodies against the virus after infection has set in. Taking the test during infection may not deliver a very confident result. An accuracy of, say, 80% still leaves one in five people with a false result. Spain recently recalled more than 8,000 Chinese-made test kits because of worries about inaccurate results. More than a dozen companies that have notified the FDA they are producing antibody tests are allowed to begin distributing the tests to hospitals and doctors’ offices, but they must carry disclaimer statements that read: “This test has not been reviewed by the FDA.” Accuracy and reliability won’t be ensured without validation and experience over time.

And because covid-19 is such a new disease, we don’t know how long immunity will last. Right now the virus seems to be mutating slowly and shouldn’t pose an annual problem like the flu, but we’ve only been studying it for a little over three months. Tony Mazzulli, chief microbiologist with Toronto’s Sinai Health, told the New York Times it’s also unclear whether antibodies would prevent infection from exposure to a large amount of the virus, as in a hospital setting.

%d bloggers like this: